The U.K. risks losing its attraction as a location for multinational drug companies if it leaves the European Union without an agreement that can guarantee the continuing smooth trade of medicines and medical devices, health industry representatives Oct. 31 told a parliamentary committee.
Failure of the U.K. to complete its “Brexit” without reaching an agreement to maintain access to the EU’s single market and customs union would create major barriers to trade, and “there is a fear that the U.K. will become less interesting to pharmaceutical firms,” Julian Maitland-Walker, a senior partner at Maitland Walker LLP, said.
“If you have ...